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Abstract: Fasciola hepatica, the causative agent of fasciolosis, is a global threat to public health, animal
welfare, agricultural productivity, and food security. In the ongoing absence of a commercial vaccine,
independent emergences of anthelmintic-resistant parasite populations worldwide are threatening
the sustainability of the few flukicides presently available, and particularly triclabendazole (TCBZ)
as the drug of choice. Consequently, prognoses for future fasciolosis control and sustained TCBZ
application necessitate improvements in diagnostic tools to identify anthelmintic efficacy. Previously,
we have shown that proteomic fingerprinting of F. hepatica excretory/secretory (ES) products offered
new biomarkers associated with in vitro TCBZ-sulfoxide (SO) recovery or death. In the current paper,
two of these biomarkers (calreticulin (CRT) and triose phosphate isomerase (TPI)) were recombinantly
expressed and evaluated to measure TCBZ efficacy via a novel approach to decipher fluke molecular
phenotypes independently of molecular parasite resistance mechanism(s), which are still not fully
characterised or understood. Our findings confirmed the immunoreactivity and diagnostic potential
of the present target antigens by sera from TCBZ-susceptible (TCBZ-S) and TCBZ-resistant (TCBZ-R)
F. hepatica experimentally infected sheep.
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1. Introduction
Fasciola hepatica, the common liver fluke and causative agent of fasciolosis, is a major zoonotic
parasitic platyhelminth of humans and their livestock within temperate regions worldwide. Liver fluke
threatens food security via acute infections, resulting in sudden flock deaths, as well as chronic infections
leading to reductions in meat and/or milk yields, fertility, and/or wool production, which together
contribute to annual global economic losses estimated to be over $3BN [1,2]. F. hepatica is also a
re-emerging food-borne disease risk to human populations, with up to 17 million people estimated
with infection and 180,000 at risk [3]. Meteorological trends associated with climate change and global
warming are expected to increase the geographic spread of this parasite, and its intermediate Lymnaeid
snail host [3], factors that are favourable for perpetual disease transmission. Thus, these climatological
and biological shifts are predicted to prompt epidemic livestock disease incidence rates in years to
come [4] and further increase public health concerns.
Triclabendazole (TCBZ) and its metabolites (−SO/−SO2) comprise the only multi-stage flukicide
agent that targets all mammalian-infective immature and mature fluke stages with high efficacy
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and broad activity [5]. Consequently, overreliance has subsequently led to global reports of TCBZ
resistance (TCBZ-R) and treatment failure in both livestock and humans [6,7]. New tools that can
determine TCBZ efficacy status are urgently needed to support TCBZ management in the absence of
vaccines and new efficacious anthelmintics [8], knowledge that will inform treatment selection and
likely prolong TCBZ shelf-life. Currently, there are no biomarkers directly associated with F. hepatica
TCBZ efficacy, as the majority of diagnostic groundwork and method development has been aimed
towards parasite detection per se and through subsequent reduction tests, for example, based on the
recovery of eggs and the detection of F. hepatica faecal antigens such as cathepsin L (CL) proteases or
other excretory/secretory (ES) proteins [9–11]. However, we have previously shown that proteomic
fingerprinting of F. hepatica ES products offers new biomarkers associated with TCBZ-sulfoxide (SO)
recovery or death [11]. In the present study, two of these biomarkers, calreticulin (CRT) and triose
phosphate isomerase (TPI), were recombinantly expressed and evaluated using experimental infection
sera as candidates of a novel molecular test platform to measure TCBZ efficacy.
2. Results
2.1. In Vitro Proteomics: Recombinant Expression and Purification
2.1.1. Calreticulin (N-Terminally Truncated, rFh∆CRT)
rFh∆CRT was overexpressed using 0.5 mM isopropyl β-d-1–thiogalactopyranoside (IPTG)
(Figure 1A, 54.9 kDa) and purified using immobilised metal ion chromatography (IMAC) (Figure 1B).
Initially, IMAC at sub-neutral pH (pH 6) was attempted, but subsequently superseded by above
neutral pH (pH 8). Isomeric separation of rFh∆CRT was noticeable and shown by 1-DE (pH-associated:
Figure 1A, at pH 6; Figure 1B at pH 8) and 2-DE (Figure 1D), which further demonstrated isoelectric
separation of these components between approximately 5.25 and 5.50 pI. Molecular weight and pI
properties were also augmented compared with predicted values for Fh∆CRT of 46.99 kDa (+1.28 kDa
including polyhisitidine tag) and 4.67 pI (+0.12 pI including polyhisitidine tag), though dimorphism
was reminiscent of previous descriptions of Trypanosoma cruzi CRT [12].
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Figure 1. Expression, purification and proteomic analysis of recombinant truncated Fasciola hepatica 
calreticulin (rFhΔCRT). FhΔCRT-pET-28b(+) BL21(DE3)pLysS lysates (5 µg) before and after 0.5 mM 
isopropyl β-D-1–thiogalactopyranoside (IPTG) induction were analysed by 1-DE (A) before 
immobilised metal ion chromatography (IMAC) purification using HIS-Select® Cobalt resin (B) over 
two operations conducted at pH 6.0, followed by further purification at pH 8.0 (not shown), to remove 
co-elutants with the target rFh∆CRT, indicated by the arrow. Transient dimorphism of rFh∆CRT at 
~48 and ~50 kDa was evident following re-purification, owing to the pH adjustment ((C), samples (A) 
vs. (B), 1.5 µg per lane). 2-DE of the nominal ~50 kDa purified sample ((D), 5 µg) (boxed/encircled) 
demonstrated further isomeric separation of this rFh∆CRT between approximately 5.25 and 5.50 pH, 
which was higher than predicted (predicted: 4.79 pI including polyhistidine tag). Both dimorphic (1-
DE, boxed) and isomeric (2-DE, encircled) proteins were confirmed as F. hepatica calreticulin by LC-
MS/MS (p < 0.01: PRJEB25283, maker-scaffold10x_1445_pilon-snap-gene-0.69.mRNA-1). 
Abbreviations: Mr, Amersham Low Molecular Weight sodium dodecyl sulfate (SDS) Calibration Kit 
(kilodaltons); FT, flow-through; 10–500 [mM] imidazole concentration. 
Figure 1. Expression, purification and proteo ic analysis of reco binant truncated Fasciola hepatica
calreticulin (rFh∆CRT). Fh∆CRT-pET-28b(+) BL21(DE3)pLysS lysates (5 µg) before and after 0.5 mM
isopropylβ-d-1–thiogalactopyranoside (IPTG) induction were analysed by 1-DE (A) before immobilised
metal ion chromatography (IMAC) purification using HIS-Select® Cobalt resin (B) over two operations
conducted at pH 6.0, followed by further purification at pH 8.0 (not shown), to remove co-elutants with
the target rFh∆CRT, indicated by the arrow. Transient dimorphism of rFh∆CRT at ~48 and ~50 kDa
was evident following re-purification, owing to the pH adjustment ((C), samples (A) vs. (B), 1.5 µg per
lane). 2-DE of the nominal ~50 kDa purified sample ((D), 5 µg) (boxed/encircled) demonstrated further
isomeric separation of this rFh∆CRT between approximately 5.25 and 5.50 pH, which was higher
than predicted (predicted: 4.79 pI including polyhistidine tag). Both dimorphic (1-DE, boxed) and
isomeric (2-DE, encircled) proteins were confirmed as F. hepatica calreticulin by LC-MS/MS (p < 0.01:
PRJEB25283, maker-scaffold10x_1445_pilon-snap-gene-0.69.mRNA-1). Abbreviations: Mr, Amersham
Low Molecular Weight sodium dodecyl sulfate (SDS) Calibration Kit (kilodaltons); FT, flow-through;
10–500 [mM] imidazole concentration.
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LC-MS/MS identified 1-DE- and 2-DE-separated rFh∆CRT isomers (Figure 1C,D: boxed/circled
protein bands/spots) as FhCRT (WormBase ParaSite (WBPS): PRJEB25283, maker-scaffold10x_1445_
pilon-snap-gene-0.69.mRNA-1). Specifically, >71.8% of all FhCRT residues were detected (
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, Figure A1),
which, when excluding the truncated signal p ptide (1–19 aa, not including Cys-18), increased to
>75.3% overall sequence coverage. On the basis of representative Sanger Sequenci g data (not shown),
a putative aspartate-asparagi e substitution was etermined (Figure A1: FhCRT, D333N; Fh∆CRT,
D316N). This was supported by peptide fragmentation analysis in the highest MASCOT scoring
LC-MS/MS submission (Figure 1D: spot 1; 1842 MASCOT score), within the MS/MS-derived peptide
D309-R339 from FhCRT (1-DVAYVGFDLWQVSSGSLFDNILLTDDPDYAR-31, 46.77% D25N verses
27.79% D19N; 14.32% D26N; 11.12% D28N). Interestingly, this sequence change is different from
another FhCRT genome project sequence (Genbank: PIS80991.1; not shown), but is conserved between
human (HsCRT) and ovine (OaCRT) host CRTs, sharing 51.9% and 51.4% overall sequence identity with
FhCRT, respectively. On the basis of sequence matching to HsCRT (Figure A1), mouse, and rabbit
CRT models [13–15] (not shown), inferences were drawn for domain allocations, including lectin
(N, 1–169 aa), proline-rich (P, 170–284 aa), and C-terminal (C, 285–400 aa) CRT domains (Figure A1).
Further residues of reported biological importance in mouse and rabbit CRTs that were fully conserved
here (Figure A1) included N-, P-, and C-based residues towards ER-based glycan interactions, protein
binding, and folding (FhCRT, Y-109, M-131, D-135, H-170, W-261, W-319), and those involved in the
formation of a disulfide bond within the N domain (FhCRT, C-105, C-137).
2.1.2. Triose Phosphate Isomerase (rFhTPI)
rFhTPI was overexpressed using 0.5 mM IPTG (Figure 2A, 29.7 kDa) and purified using IMAC
(Figure 2B). 1-DE indicated the majority of protein resolution was monomeric and with minor
dimerization (Figure 2C), likely owing to the absence of cross-linkers [16]. 2-DE demonstrated six
rFhTPI isoforms separated between approximately 7.50 and 8.10 pI (Figure 2D), properties that were
higher than the predicted values for rFhTPI of 27.78 kDa (+1.71 kDa including polyhistidine tag) and
8.07 pI (−1.18 pI including polyhistidine tag).
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LC-MS/MS identified 1-DE- and 2-DE-separated rFhTPI isomers (Figure 2C,D: boxed/circled) as
FhTPI (GenBank, AGJ83762.1), including >86.5% of FhTPI residues (
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of functional and structural importance were shown between the three sequences studied here.
2.2. Western Hybridisation
Immunodiagnostic evaluations of rFh∆CRT and rFhTPI were conducted via western hybridisation
with 0.25 µg/lane. Antigens were probed with serum pooled from experimental infections (day 0–119;
0–17 weeks post infection (wpi)) in sheep (dosed with 250 metacercariae), with one each of
three TCBZ-susceptible (TCBZ-S) (Aberystwyth, Italian, Miskin) or TCBZ-R (Kilmarnock, Penrith,
Stornoway) F. hepatica strains. Whole sera were probed and IgG binding was detected using the
5–bromo-4–chloro-3–indolyl-phosphate and nitro blue tetrazolium (BCIP/NBT) system (Figure 3).
To improve the sensitivity of immunoreactivity for interpretation, bands were quantified using
ImageQuant TL (GE Healthcare Life Sciences, UK) via band intensity values, whereby 0 wpi values
were subtracted from 1 to 17 wpi values per blot and averaged between duplicate western hybridisations
to determine the overall immunoreactivity (negative, −; positive, +).
Blots indicated differential immunoreactivity between candidates, indicating F. hepatica TCBZ
efficacy-dependent differences and temporal changes in native antigen abundance and exposure
post-infection, reflected by IgG reactivity to recombinant biomarkers (Figure 3). TCBZ-S-specific sera
demonstrated antibody-rFh∆CRT binding at 1, 9, 12, and 15 wpi (Figure 3A), whereas TCBZ-R-specific
sera indicated rFh∆CRT recognition at 3, 7–8, 14–15, and 17 wpi (Figure 3B). rFhTPI indicated limited
immunoreactivity with both sets of sera, though positivity was evident first in TCBZ-R infection at 7, 9,
10, 13, and 15–17 wpi (Figure 3D) compared with TCBZ-S-specific sera positivity at only 11–12 wpi
(Figure 3C).
TCBZ-induced variations in the test antigens were measured by IgG positivity following
anthelmintic administration at 12 wpi, with changes to IgG patterns due to the induction and half-life of
IgG additionally considered, both nominally three weeks in duration. As a result of these prerequisites,
reduced or terminated (TCBZ-S phenotype) and continued or augmented (TCBZ-R phenotype)
biomarker abundances were expected as a reflection of their involvement during TCBZ-induced
killing (causing IgG induction) or survival (causing IgG reduction and triggering IgG titre decrease)
phenotypes, respectively. The negativity observed during TCBZ-S fluke infection against rFhTPI, except
during fluke patency expected at 11–12 wpi, indicates ablated FhTPI abundance post-treatment that
fits the expected TCBZ-S phenotype (Figure 3C). Furthermore, anti-rFhTPI IgG positivity overlapping
juvenile, adult, and TCBZ administration phases during TCBZ-R infection suggests persisting FhTPI
production and immune exposure in the TCBZ-R versus TCBZ-S phenotype (Figure 3D).
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immunogenicity testing against triclabendazole-susceptible (TCBZ-S) and TCBZ-resistant (TCBZ-R)
Fasciola hepatica-infected sheep IgG. rFh∆CRT (0.25 µg/lane) (A,B) and rFhTPI (0.25 µg/lane) (C,D)
were probed with whole sheep sera diluted to 1:1500 and pooled from three animals experimentally
infected with TCBZ-susceptible (TCBZ-S; A,C) or TCBZ-resistant (TCBZ-R; B,D) F. hepatica isolates,
and subsequently detected for IgG binding via the 5–bromo-4–chloro-3–indolyl-phosphate and nitro
blue tetrazolium (BCIP/NBT) system. Data from duplicate western hybridisations were analys d (i–ii)
and band areas of inter st were quantified using ImageQuan TL (GE H althcare Life Sciences, UK),
which calculated positivity (+) r negativity (−) by subtracting 0 we ks pos infection (wpi) values
from each wpi value for each treatment, whereby values that were negative, or negative and positive in
both replicates, were considered negative. Nitrocellulose membrane (NCM) transfer of 1-DE-separated
recombinant proteins was confirmed using Amido Black staining. Abbreviations: Mr, Amersham Low
Molecular Weight SDS Calibration Kit (kilodaltons); 0–17, weeks post-infection; *, TCBZ administration.
3. Discussion
The crisis in fasciolosis management inspires the development of new diagnostic approaches,
especially for the detection of TCBZ-R F. hepatica strains. Critical levels of TCBZ resistance are now
reported worldwide [6,7] and are appearing at a rate that is set to increase alongside fluke incidence as
a result of climate change [4,21,22]. As it stands, existing coprological, immunological, and molecular
test options are unsuitable for on-field-based and point-of-care settings, which have long been an
established practice for some other neglected tropical diseases [23], but only recently considered a
goal for fasciolosis control [24,25]. On-farm monitoring of anthelmintic efficacy status will be a key
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component in regaining control over liver fluke infections via prolonging TCBZ shelf-life. To this end,
our targeted molecular diagnostic pipeline tested two novel biomarkers of reported in vitro TCBZ-SO
efficacy association [26] and confirmed in vivo immune signal exposure, providing a baseline upon
which further field-based and point-of-care tests can be developed for infection and anthelmintic
efficacy diagnoses.
rFh∆CRT and rFhTPI were recombinantly expressed and purified (Figures 1 and 2), exhibiting
analogous molecular properties as previously observed with native proteins ex vivo [26].
Bioinformatic analysis of FhTPI, following on from previous detailed biochemical evaluations [16],
demonstrated the conservation of key residues pertaining to important TPI-specific structural and
functional properties (Figure A2). Similar predictions and sequence comparisons for rFh∆CRT showed
similarly high conservation of multiple residues of importance, and DNA sequencing and mass
spectrometry data CRT confirmed a possible aspartate–asparagine residue substitution distinct
from genome-derived sequences (Figure A1). Furthermore, investigation of potential antigenic
cross-reactivity with human and ovine host orthologues found <70% similarity between all sequence
comparison despite biologically important residue conservation, including sequence identities of
51.4–51.9% for FhCRT and 68.6% for rFhTPI.
Following the study by Morphew et al. [26], who identified several ES-derived proteins following
in vitro sublethal (SL) or lethal (L) TCBZ-SO treatment, FhCRT recovery post-SL TCBZ-SO was
putatively associated with survival in a virulence capacity, whereas L TCBZ-SO-induced treatment
and FhTPI identification was presumed to be a biomarker of TCBZ susceptibility through an
involuntary mechanism of internal and housekeeping protein exposure. Translation of these findings
to an in vivo scenario was necessary to delineate the fluke’s complex molecular dynamics during
parasite–host interactions and following treatment. To this end, anti-biomarker host IgG patterns
against rFh∆CRT and rFhTPI were quantitatively determined from western hybridisations using sera
of representative experimental TCBZ-S and TCBZ-R F. hepatica sheep infections (0–17 wpi), including
TCBZ administration at 12 wpi. IgG positivity in the three weeks prior to 15 wpi in TCBZ-R sera against
both biomarkers (Figure 3B,D) precluded definitive TCBZ-induced IgG recognition, as these could have
resulted from continued antigen abundances or sustained IgG titres from previous exposures. However,
TCBZ-R IgG against rFh∆CRT was negative between 9 and 13 wpi, but positive at 14–15 wpi, suggesting
possible association of FhCRT with TCBZ challenge in the TCBZ-R phenotype (Figure 3B) and an
ambiguous role following TCBZ treatment in the TCBZ-S infection phenotype (Figure 3A). Despite no
evidence for TCBZ-S or TCBZ-R parasite-infected anti-antigen IgG specificity (Figure 3), anti-FhCRT
IgG was detected at different intervals during TCBZ-S and TCBZ-R phenotype infections, including
before and after TCBZ treatment, suggesting a multifaceted role of FhCRT towards housekeeping
and/or virulence that is heightened or sustained during anthelmintic challenge. Conversely, anti-FhTPI
IgG detection at multiple timepoints during infection with TCBZ-R compared with TCBZ-S parasites
was indicative of heightened glycolytic activity or moonlighting roles by FhTPI, potentially supported
by the negativity of anti-FhTPI IgG following TCBZ administration in the TCBZ-S infection sera.
FhCRT immunoreactivity was in keeping with previous strong CRT immunogenicity
observations [27,28] and, particularly, recognition by TCBZ-R (Figure 3B) was in line with previous
reports of CRT virulence association [28,29] and molecular phenotypes of drug-resistant cancer
cells [30–32]. However, similarly to the influx of stress-response proteins during infection [33] and
following TCBZ administration [26,34], FhCRT secretion during TCBZ-S infection, including after
TCBZ at 15 wpi (Figure 3A), could be attributed to CRT’s nominal house-keeping functionalities. As a
result of roles involving calcium homeostasis [35,36], glycoprotein and misfolded protein binding and
chaperoning [37,38], and cellular recovery [37–40], CRT may have far-reaching direct and indirect roles,
especially if the influence of FhCRT spans across the binding of factors with known roles in virulence,
metabolic, or nutritional benefit and TCBZ response association, including cyclophilin A, glycolytic
enzymes, and fatty acid binding proteins [26,34].
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Similarly, different guises of glycolytic enzyme secretion under certain circumstances have been
linked to pathogen virulence [41,42] as well as apoptosis [43], though TPI has so far only been linked
to the latter process. It was thus expected that TPI would have a limited role and exposure during the
TCBZ-R phenotype as per its anticipated internal, hidden antigen hallmarks and its overabundance in
TBCZ-S fluke ES following in vitro L TCBZ-SO treatment [26]. However, as FhTPI recognition was
more evident during TCBZ-R versus TCBZ-S fluke infection (Figure 3C,D), with anti-FhTPI IgG after
TCBZ administration in the TCBZ-R group only, this suggests active secretion patterns irrespective of
TCBZ challenge and presents as a potential biomarker of TCBZ-R fluke viability and TCBZ efficacy.
Molecular processes driving the observed TCBZ-S and TCBZ-R fluke infection and anthelmintic
phenotypes, evidential FhCRT and FhTPI secretion in the lack of TCBZ administration, and FhTPI
secretion following TCBZ administration by TCBZ-R flukes were intriguing. However, the diagnostic
roles of FhCRT and FhTPI studied within the current TCBZ-S and TCBZ-R molecular profiles
present some ambiguity, which invites further study to clarify their roles during F. hepatica infection
towards virulence, nutrition, and/or xenobiotic metabolic processes. Moreover, and towards further
diagnostic validation, future direct determinations of antigen abundance in host samples in response
to anthelmintic application would be an ideal progression from this study, in order to provide
representative and measurable changes in the TCBZ-S and TCBZ-R molecular phenotypes during
infection and following TCBZ challenge. Together, these findings have identified multiple, descriptive
elements of the changing proteomic molecular phenotype by TCBZ-S and TCBZ-R flukes during
sheep infection and following TCBZ challenge, shown through the detection of anti-FhCRT and FhTPI
IgG antibodies.
4. Materials and Methods
4.1. Cloning and Recombinant Protein Expression
The calreticulin gene sequence was identified in the Fasciola hepatica genome (WormBase
ParaSite (WBPS) v14, parasite.wormbase.org; PRJEB25283: FhCRT, maker-scaffold10x_1445_pilon-
snap-gene-0.69.mRNA-1 (WBPS v9: PRJEB6687, BN1106_s2673B000071.mRNA 1) for primer designs,
including truncation of the N-terminal signal peptide (Fh∆CRT). cDNA was used for PCR (MyFi™,
Bioline, UK) and amplicons were cloned using pGEM®-T Easy (Promega, UK) and alpha-select
bronze efficiency cells (Bioline, UK) with ampicillin selection (100 µg/µL) (LB-agar, Melford, UK; LB
broth, Sigma-Aldrich, UK), according to the manufacturer’s guidelines. Plasmids were extracted
(ISOLATE II Plasmid Mini Kit, Bioline, UK) to introduce NdeI and NotI sites via PCR and cloned as
before prior to restriction digestion (Thermofisher, UK) and ligation with complementarily-linearised
pET-28B+ (Merck Millipore, Germany), as recommended by the manufacturers. Prepared expression
plasmids FhTPI-pET-46 Ek/LIC [16], gifted by Professor David Timson (University of Brighton,
UK), and Fh∆CRT-pET-28B+ were confirmed via triplicate Sanger sequencing (conducted in-house),
including polyhistidine sequences at N- or C-termini (N: FhTPI, 5′-MAHHHHHHVDDDDK-3′;
C: Fh∆CRT, 5′-AAALEHHHHHH-3′). Protein molecular weight and pI (accounting for polyhistidine
tag) were predicted using ExPASy (web.expasy.org/compute_pi).
Fh∆CRT-pET-28B(+) was transformed into BL21(DE3)pLysS cells (Promega, UK) maintained with
kanamycin (50 µg/µL) and FhTPI-pET-46 Ek/LIC was transformed into One Shot® BL21(DE3) Star™
cells (Thermofisher, UK) maintained with ampicillin (100 µg/µL). For recombinant expression, liquid
cultures were diluted (1:70) into fresh Luria-Bertani (LB) broth with appropriate antibiotic selection
and grown until reaching 0.6–1.0 A600 cell density. Following induction of expression with isopropyl
β-d-1–thiogalactopyranoside (IPTG) (0.1–1 mM), cultures were incubated at 37 ◦C and shaking at
150 revolutions per minute for five hours. Cells were collected by pelleting at 10,000× g at 4 ◦C for
10 min, and then resuspended in cold lysis buffer (0.1 M sodium phosphate, pH 7.4; 0.4 M sodium
chloride; 5 mM magnesium chloride). For lysis, cells were subjected to three cycles of freeze–thawing
in liquid nitrogen followed by three cycles of sonication and resting on ice for 15 s each. Crude soluble
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proteins were filtered with 0.22 µm polyethersulfone (Merck Millipore, Darmstadt, Germany) before
polyhisitidine-tagged protein purification using immobilised metal ion chromatography (IMAC) with
HIS-Select® Nickel (FhTPI) or Cobalt (Fh∆CRT) (P6611 and H8162, Sigma-Aldrich, Gillingham, UK),
with the procedure conducted as recommended by the manufacturer and with elutions tested using
50–500 mM imidazole. Purified IMAC fractions were filtered using Amicon® Ultra 10K or 30K
Centrifugal Filters (Merck, Gillingham, UK), as recommended by the manufacturer, and resuspended
in ultrapure water (18.2 MΩ).
4.2. Proteomics and Western Hybridisation
Protein concentrations were calculated using the Bradford assay [44] and fractions were analysed
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) as follows, alongside the
Amersham Low Molecular Weight SDS Calibration Kit (GE Healthcare Life Sciences, Amersham,
UK; 14.4–97.0 kilodaltons, kDa) as recommended by the manufacturer. For 1-DE, 0.1–2 µg purified
protein was used in 1–20 µL volume with SDS buffer (69.45 mM tris-HCl, pH 6.8; 11.1% (v/v) glycerol;
1% (w/v) SDS; 0.005% (w/v) bromophenol blue) including β–mercaptoethanol (100 mM) or dithiotreitol
(DTT) (50 mM). For 2-DE procedures, 1–5 µg purified protein in 125 µL buffer A (8 M urea; 2% w/v
CHAPS; 33 mM dithiotreitol (DTT); 0.5% v/v carrier ampholytes (Biolyte 3–10, Bio-Rad, Watford,
UK)) was allowed to passively rehydrate 7 cm linear pH 3–10 IPG strips (Bio-Rad, UK) at room
temperature overnight. Rehydrated strips were isoelectrically focused at 10,000–11,000 Vh using a
Protean Mini IEF Cell (Bio-Rad, UK) to separate protein samples in the first dimension, then equilibrated
in buffer B (50 mM tris-HCl; 6 M urea; 30% (w/v) glycerol; 2% (w/v) SDS) containing DTT (10 mg/mL)
for 15 min, and then buffer B containing IAA (25 mg/mL) for a further 15 min. Electrophoresis
was conducted at ambient temperature using the Protean Mini Tetra System (Bio-Rad, UK) in [1X]
tris-glycine SDS buffer. Samples were aliquoted into wells (1-DE) or IPG strips were overlaid in molten
agarose (0.5% (w/v) agarose; 0.125 M tris (pH 6.8); (100 mg/mL) bromophenol blue) (2-DE) prior to
electrophoretic separation at 75 V through a stacking gel (4.5% acrylamide; 0.5 M tris, pH 6.8; 0.4%
(w/v) SDS), followed by 150 V through the resolving gel (12.5% acrylamide; 1.5 M tris, pH 8.5; 0.4%
(w/v) SDS) as required. Gels were fixed (10% (v/v) acetic acid; 40% (v/v) ethanol) and stained with
Coomassie™ blue (PhastGel Blue R, Amersham Biosciences, Amersham, UK) with 10% (v/v) acetic
acid and 30% (v/v) methanol or Coomassie™ blue solution (QC Colloidal Coomassie™, Bio-Rad),
and then destained in 1% (v/v) acetic acid as required. Images were taken using a Typhoon™ FLA 9500
(GE Healthcare Life Sciences, Amersham, UK) using the digitization system for Coomassie™ Blue
staining or using a Bio-Rad GS-800™ calibrated densitometer (Bio-Rad, UK) alongside Quantity One®
software (v4.6.9). Protein molecular weights were calibrated against the Amersham Low Molecular
Weight SDS Calibration Kit using ImageQuant TL imaging analysis software (v8.1, GE Healthcare Life
Sciences, Amersham, UK).
For protein identification, in-gel tryptic digestion was conducted prior to analysis by liquid
chromatography tandem mass spectrometry according to the method previously described by
Davis et al. [45], including duplicate samples for 1-DE-separated mono-morphic rFhTPI monomer
and dimer bands in addition to negative gel piece controls for 1-DE and 2-DE sample preparation
methods. Data files were submitted to a MASCOT MS/MS ions search (Matrix Science) against the
F. hepatica genome (PRJEB6687, WBPS v9; cross-referenced and matched to PRJEB25283, WBPS v14)
with search parameters as previously described [45], except allowing for 2+, 3+, or 4+ charged peptide
residues and including a decoy search with each submission. The mass spectrometry proteomics
data were deposited to the ProteomeXchange Consortium via the PRIDE [46] partner repository with
the dataset identifier PXD017848 (DOI:10.6019/PXD017848), and details of sample nomenclature are
available in the Supplementary Material (Table S1). Where required, F. hepatica biomarker DNA and
protein sequences of interest identified from DNA sequencing and mass spectrometry, as well as host
protein orthologs, were aligned and annotated using BioEdit (v7.0.5.3, [47]), Clustal Omega ([48]),
and BOXSHADE (v3.2, ExPASy; embnet.vital-it.ch/software/BOX_form.html).
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For western hybridisation procedures, 1-DE-separated samples (0.25 µg/lane) were transferred to
nitrocellulose membrane (NCM 0.45 µm; GE Healthcare Life Sciences, Amersham, UK), which was
confirmed by Amido Black staining, and membranes were prepared according to the method by
Morphew et al. [11], with antibodies tested as follows. TCBZ-S and TCBZ-R F. hepatica-infected sera
were used for primary antibody incubations, which were provided by Ridgeway Research Ltd. from
three sheep infected (250 metacercariae dose) with one of three confirmed strains displaying phenotypes
of TCBZ-S (Italian, Italy; Aberystwyth and Miskin, UK) or TCBZ-R (Kilmarnock, Penrith and Stornoway,
UK). Parasites used for these infections were confirmed as TCBZ-R or TCBZ-S by Ridgeway Research
Ltd. using faecal egg count reduction tests and in vitro TCBZ-SO exposure. The serum of all sheep was
collected weekly during the course of infection from week 0 (uninfected) until week 17, including TCBZ
treatment at 12 weeks post infection (wpi). All procedures performed on sheep (project licenses PPL
40/3593, P6D805744, and PA09B4E45) adhered to the United Kingdom Home Office Animals (Scientific
Procedures) Act of 1986 as well as the European Union Animals Directive 2010/63/EU, and were
approved by Ridgeway Research Ltd.’s Animal Welfare and Ethical Review Bodies. Sera were pooled
per time point in each TCBZ-S/-R group to measure general immunoreactivity against the two F. hepatica
antigens in these pilot tests, similarly to other studies investigating diagnostic efficacy and infection
dynamics [49,50]. Primary serum antibodies were diluted to 1:1500 and incubated with membranes at
room temperature for an hour prior to an incubation with anti-sheep secondary antibodies (1:30,000;
anti-sheep IgG produced in donkey, A5187, Sigma-Aldrich, UK). Positive serum IgG binding was
detected with 5–bromo-4–chloro-3–indolyl-phosphate (BCIP; Sigma-Aldrich, UK) and nitro blue
tetrazolium (NBT; Thermo Scientific, UK) dissolved in alkaline phosphatase substrate solution (100 mM
tris-HCl, pH 9.5; 100 mM NaCl; 5 mM MgCl2), until stopping in ultrapure water (18.2 MΩ), and using
anti-histidine tag antibody (SAB1306082, Sigma-Aldrich, UK) (data not shown). Images of blots were
taken using a Bio-Rad GS-800™ calibrated densitometer (Bio-Rad, UK) using default settings for
alkaline phosphatase and exported via Quantity One® software (v4.6.9). Positivity was ascertained
following band quantification using ImageQuant TL imaging analysis software (v8.1), whereby band
intensity was calculated following the subtraction of 0 wpi values from each wpi value, and data were
summarised from duplicate western hybridisations, whereby values that were negative, or negative
and positive in both replicates, were considered negative.
5. Conclusions
Our findings from immunologic testing with experimental infection sera revealed new evidence
of the dynamic changes in the molecular proteome of infecting Fasciola hepatica, identified through IgG
immunoreactivity. There were not only distinct differences over the course of infection (0–17 weeks)
pertaining to test antigens rFh∆CRT and FhTPI, but further distinguishable IgG recognition patterns
between TCBZ-S or TCBZ-R F. hepatica parasite infection and following TCBZ administration at 12 wpi.
Specifically, evidence for in vivo FhCRT and FhTPI exposure was demonstrated during both TCBZ-S/R
parasite infections in spite of TCBZ challenge and prior to anthelmintic administration, identifying
these antigens as intriguing components of the molecular proteome that have eluded diagnostic
research focus until now. Thus, recombinant and endogenous FhCRT and FhTPI possess diagnostic
potential and, with test development, could permit differentiation between TCBZ-S and TCBZ-R liver
fluke populations.
Supplementary Materials: The following are available online. Table S1: Detailed nomenclature of rFh∆CRT and
rFhTPI mass spectrometry samples, submitted using PRIDE [46] to the ProteomeXchange Consortium (dataset
identifier: PXD017848, DOI:10.6019/PXD017848).
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(residues above ∆: FhCRT, D333N; Fh∆CRT, D316N). Alignment of FhCRT with human (P27797) and 
ovine (W5PJG7) host proteins was conducted to identify sequence identity of 51.9% and 51.4%, 
respectively. On the basis of studies of human and mouse CRTs [51], N (1–169 aa), P (170–284 aa), and 
C (285–400 aa) calreticulin domains are shown, and further residues of known functional (as 
highlighted: Y-109, M-131, D135, H-170, W261, W-319) and both structural and functional (as 
highlighted: C-105, C-137) importance were fully conserved in FhCRT and OaCRT. Abbreviations: *, 
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GenBank, AGJ83762.1) based on 2-DE and duplicate 1-DE separated proteins (Figure 3C,D) that 
matched 86.5% FhTPI residues (GenBank, AGJ83762.1). Alignment of FhTPI with human (P60174) 
and ovine (W5P5W9) host proteins was conducted to identify sequence identity of 68.6% for both. 
Putative residues involved in structural and functional roles were indicated based on matching to 
HsTPI [17–20], including the TPI active site (FhTPI, A-167-T-176), and residues for dimerization 
(FhTPI, T-76, E-98), catalysis (FhTPI, K-14), or both processes (FhTPI, H-86, E-169), residues that were 
completely conserved between all three sequences here. Abbreviations: *, conserved; strongly semi-
conserved; weakly semi-conserved.  
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